Abnormal glucose metabolism in patients treated with antipsychotics.
about
What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretionEffect of combined treatment with clozapine and metformin on fasting blood glucose, insulin level, and expression of the glucose transporter-2 (GLUT2) in Sprague-Dawley rats.Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsPatterns of physical co-/multi-morbidity among patients with serious mental illness: a London borough-based cross-sectional study.Changes in body weight, body composition and cardiovascular risk factors after long-term nutritional intervention in patients with severe mental illness: an observational study.S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin ResistanceWeight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.What is type 2 diabetes?Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Effect of Early Intervention with Omega-3 on Insulin Resistance in Patients Initiated on Olanzapine with either Sodium Valproate or Lithium: A randomized, Double-blind, Placebo-Controlled Trial.Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Affective Disorders, Bone Metabolism, and Osteoporosis.Metabolic syndrome in people with schizophrenia: a review.Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary EvidenceA UK consensus on the administration of aripiprazole for the treatment of mania.Pharmacotherapy for schizophrenic inpatients in East Asia--changes and challenges.The effect of bariatric surgery on psychiatric course among patients with bipolar disorder.Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow upWeight gain in antipsychotic-naive patients: a review and meta-analysis.Pharmacogenetic considerations in the treatment of psychiatric disorders.The Current Status of the Ketogenic Diet in Psychiatry.Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda.International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia.A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia.Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes.Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.A case of pancreatitis associated with aripiprazole in the absence of hyperglycemia.Effect of micronutrients on behavior and mood in adults With ADHD: evidence from an 8-week open label trial with natural extension.Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain.Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study.Diet and exercise effects on aerobic fitness and body composition in seriously mentally ill adults.Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population.Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells
P2860
Q28083512-F7D7F4A7-AEF8-4FAB-9954-7DA0F80CD172Q28252428-281F3FBB-310A-4F1B-85EB-93DAA24425D2Q33744440-C732792E-8620-4EB3-B590-CCE1E20E6DCDQ33765864-25308670-C300-4F3B-A81F-95DD6FF6A8C6Q33773981-45EF08EF-A1D9-4AE7-B3F8-31C824E7C910Q33824146-93E5AF85-EDC6-4DB8-B7A6-66E9FECDA53CQ33984573-B4F79649-9D0E-423C-A783-0347ACFEBAA9Q34033259-7F96B537-5310-4F96-B398-90C3E45B6423Q34623350-3CB2FA28-54EC-473D-9C40-213C40DFD9FCQ34777344-113544A7-8403-4B16-B6EB-AA6BA2898767Q35030930-636E75E8-694D-4A6C-A314-232558ABCB21Q35115972-D7A9CB9A-89D7-4A82-8094-4F8976B13C56Q36197756-3B09C718-4DD2-4B9C-8ACA-08EB193FC0B1Q36198276-7B655CF0-BB32-4E5A-AFC5-4FCD58AF3598Q36474147-D7F3898A-D510-4390-9DEF-68696FD62BE6Q37027277-577F94A5-6EB9-4DE3-9ECD-60E40C762B19Q37129646-55D9BD68-2E52-44C4-B1A8-4AC476AEEBE0Q37178192-B482A391-C7DF-4FB9-8BA5-42777DE58827Q37326130-6B877854-F970-4F53-A688-8284E1E77D5BQ37326610-24626B5F-3668-401B-B856-27FBC425FB3CQ37351069-E1CF7CBD-07D2-45C4-88F0-9690D4379584Q37494988-7867F558-75F2-48B3-BC44-AEEABF2FF2A9Q37572952-7FC5F89D-D074-4E80-AF06-547DF550C711Q37681573-D42546BA-838B-4DB1-8B54-91BF6A3F01E8Q37710385-6EE668F3-7EFD-4DBD-A849-E088C750E0BBQ37863532-D4573252-36B4-4BD9-A833-982AE239C305Q37940519-1C05C2CC-8C4C-4C33-909C-082181793E0CQ38150568-CB8A1B68-64A1-4D05-B0C8-221742677B06Q38958076-ED86D1EE-3252-4C2C-9549-A80F2E9E8F49Q40050322-090808A5-BC30-4FBC-9067-535256932DDFQ41587365-D26E5FC8-A140-4E7E-85A3-0001EF7A8A6FQ42081464-8F14389D-45D8-4F24-853C-7BD3D05194D9Q42645625-4EEB2975-1361-4969-8279-F898FE082B01Q43613438-1C1BA31D-B08A-4CC0-BB1F-2B40F839E3CDQ47213104-99352BCE-E83E-4F26-BBBB-5265E5DAAEC4Q47266669-EA81E27C-7ED6-4A68-B954-B48D2470AD27Q50674176-190BA65E-4E9B-4B3B-9A09-91C96401E27CQ51391762-ACC389E1-F6B9-4652-B36E-2676597F6486Q55058612-FF212691-73E2-4F9B-BDCA-2D3C11A43C2FQ57253280-FF48F2C5-4B77-4CCA-ABAB-5F561BA5C2F0
P2860
Abnormal glucose metabolism in patients treated with antipsychotics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Abnormal glucose metabolism in patients treated with antipsychotics.
@en
type
label
Abnormal glucose metabolism in patients treated with antipsychotics.
@en
prefLabel
Abnormal glucose metabolism in patients treated with antipsychotics.
@en
P1476
Abnormal glucose metabolism in patients treated with antipsychotics.
@en
P2093
P304
P356
10.1016/J.DIABET.2007.01.003
P577
2007-04-06T00:00:00Z